Zoetis Inc. $ZTS Shares Sold by Cidel Asset Management Inc.

Key Points

• Cidel Asset Management cut its Zoetis stake by 97.7% in the second quarter, selling 146,487 shares and retaining 3,408 shares valued at approximately $245,000. Institutional investors collectively own 92.8% of Zoetis.
• Analyst sentiment is mixed: Zoetis has a consensus “Hold” rating from 19 analysts, with an average price target of $101.08. Recent target reductions included TD Cowen, Barclays and JPMorgan, while Zacks downgraded the stock to “Strong Sell.”
• Zoetis shares opened at $73.05, near their 12-month low of $71.00 and well below the 12-month high of $150.05. The company recently exceeded quarterly EPS estimates, reporting $1.87 versus the $1.85 consensus, although revenue declined slightly year over year.

Cidel Asset Management Inc. lowered its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 97.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,408 shares of the company's stock after selling 146,487 shares during the period. Cidel Asset Management Inc.'s holdings in Zoetis were worth $245,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after purchasing an additional 2,978 shares during the period. Empowered Funds LLC raised its holdings in Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company's stock valued at $1,859,000 after buying an additional 657 shares during the period. Intech Investment Management LLC lifted its position in Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company's stock valued at $1,374,000 after buying an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC lifted its position in Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company's stock valued at $522,000 after buying an additional 1,422 shares in the last quarter. Finally, Glenview Trust co grew its stake in Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company's stock worth $745,000 after buying an additional 506 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ZTS. TD Cowen reduced their target price on shares of Zoetis from $104.00 to $94.00 and set a "buy" rating on the stock in a report on Tuesday, August 25th. Cantor Fitzgerald set a $94.00 price target on Zoetis in a report on Tuesday, August 25th. Barclays cut their price objective on Zoetis from $136.00 to $85.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 1st. JPMorgan Chase & Co. reduced their price objective on Zoetis from $130.00 to $115.00 and set an "overweight" rating on the stock in a research note on Friday, August 7th. Finally, Zacks Research downgraded Zoetis from a "hold" rating to a "strong sell" rating in a research report on Monday, August 10th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $101.08.

Zoetis Trading Up 0.3%

NYSE ZTS opened at $73.05 on Friday. Zoetis Inc. has a 12 month low of $71.00 and a 12 month high of $150.05. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company has a market capitalization of $30.19 billion, a price-to-earnings ratio of 12.03, a price-to-earnings-growth ratio of 1.70 and a beta of 0.73. The company's fifty day moving average price is $75.56 and its two-hundred day moving average price is $91.97.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the previous year, the firm earned $1.76 EPS. The company's revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company's product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.